Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

First Posted Date
2008-02-22
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
393
Registration Number
NCT00620867
Locations
🇺🇸

Pfizer Investigational Site, Danville, Virginia, United States

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

First Posted Date
2008-02-13
Last Posted Date
2012-12-13
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
11
Registration Number
NCT00614406
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

First Posted Date
2008-02-06
Last Posted Date
2013-03-05
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
10
Registration Number
NCT00608595
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Veterans Administration, Nashville, Tennessee, United States

COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma

First Posted Date
2008-01-29
Last Posted Date
2008-01-29
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
122
Registration Number
NCT00603759
Locations
🇮🇷

Department of Chemoradiation, Tehran, Iran, Islamic Republic of

Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee

First Posted Date
2008-01-18
Last Posted Date
2008-01-18
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
30
Registration Number
NCT00597415
Locations
🇺🇸

University Hospitals Case Medical Center, Beachwood, Ohio, United States

Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-01-16
Last Posted Date
2015-12-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
12
Registration Number
NCT00596219

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma

First Posted Date
2008-01-14
Last Posted Date
2012-08-31
Lead Sponsor
Boston University
Target Recruit Count
10
Registration Number
NCT00592319
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

Phase 2
Conditions
First Posted Date
2008-01-09
Last Posted Date
2013-12-18
Lead Sponsor
National Cancer Centre, Singapore
Target Recruit Count
35
Registration Number
NCT00589186
Locations
🇸🇬

National Cancer Centre - Singapore, Singapore, Singapore

The Effects of Celecoxib on Bone Ingrowth

Early Phase 1
Terminated
Conditions
Interventions
First Posted Date
2008-01-03
Last Posted Date
2016-03-14
Lead Sponsor
University of Utah
Target Recruit Count
9
Registration Number
NCT00585156
Locations
🇺🇸

Veteran Affairs (VA) Medical Center, Salt Lake City, Utah, United States

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-01-03
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
106
Registration Number
NCT00585312
Locations
🇬🇧

Pfizer Investigational Site, Harrow, Middlesex, England, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath